Coronavirus Vaccine

Safety of mRNA COVID-19 jabs backed, despite myocarditis cases

As US and EU health regulators review cases of heart inflammation seen in young people administered mRNA-based COVID-19 vaccines from Pfizer/BioNTech and Moderna, cardiologists have come out in favour of the jabs. The American Heart Association (AHA) and American Stroke Association (ASA) have issued a statement saying that the benefits of the vaccines “enormously outweigh …

Safety of mRNA COVID-19 jabs backed, despite myocarditis cases Read More »

UK says Pfizer, AZ COVID-19 vaccines work against Indian variant

People who have received two doses of the AstraZeneca or Pfizer/BioNTech COVID-19 vaccines have good protection against the Indian variant of SARS-CoV-2 , according to new UK data. The Pfizer/BioNTech shot provided 88% protection against the B.1.617.2 variant first identified in India and currently gaining ground across the UK and other countries around the world, …

UK says Pfizer, AZ COVID-19 vaccines work against Indian variant Read More »

UK booster trial will test value of third COVID jab dose

All seven COVID-19 vaccines ordered by the UK government will be tested in a new trial that will see whether they can be used as a third booster dose to protect against new variants.  The Cov-Boost trial is thought to be the first in the world to try to generate data on the value of …

UK booster trial will test value of third COVID jab dose Read More »

Medicago, GSK’s plant-made COVID jab clears phase 2

Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now hoping to have phase 3 data available “by early summer.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around …

Medicago, GSK’s plant-made COVID jab clears phase 2 Read More »

EMA panel probes heart inflammation with Pfizer/BioNTech COVID vaccine

A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the Pfizer/BioNTech Comirnaty shot.  The Pharmacovigilance Risk Assessment Committee (PRAC) says it is aware of cases of myocarditis and pericarditis – inflammation of the heart muscle and membrane around the …

EMA panel probes heart inflammation with Pfizer/BioNTech COVID vaccine Read More »

Pfizer says COVID-19 jab could rake in $26bn this year

Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world’s biggest-selling medicines.  The company also said that it doesn’t expect the massive sales to be a one-off, as demand from governments around the world for coronavirus vaccines will continue to be …

Pfizer says COVID-19 jab could rake in $26bn this year Read More »

FDA pens stinging report on Emergent COVID vaccine plant

Emergent BioSolutions’ difficult month has been made worse by an FDA report into its facility in Baltimore, which has been blamed for the wastage of millions of doses of Johnson & Johnson’s COVID-19 vaccine.  The US regulator says it completed an inspection of the Bayview plant run by the contract manufacturing organisation (CMO) which uncovered …

FDA pens stinging report on Emergent COVID vaccine plant Read More »

EU orders another 100m doses of Pfizer/BioNTech COVID jab

The EU has continued a refocus of its COVID-19 vaccination drive on mRNA shots, ordering another 100 million doses of Pfizer and BioNTech’s Comirnaty shot.  The new deal takes the total number of Comirnaty shots ordered by the EU for delivery this year to 600 million, and comes amid an ongoing debate about the safety …

EU orders another 100m doses of Pfizer/BioNTech COVID jab Read More »

US seeks halt on J&J COVID vaccine rollout as clot concerns spread

US health authorities have recommended pausing dosing with Johnson & Johnson’s COVID-19 vaccine as they investigate cases of blood clots also observed in some people taking the AstraZeneca shot.  The FDA said there had been reports of six cases of cerebral venous sinus thrombosis (CVST) associated with low blood platelet counts (thrombocytopenia) out of more …

US seeks halt on J&J COVID vaccine rollout as clot concerns spread Read More »

UK will offer under-30s alternative to AZ’s COVID jab

The UK drugs regulator has said people aged under 30 should be offered an alternative to the AstraZeneca COVID-19 vaccine, because of evidence linking it to rare blood clots.  Updated figures from the Medicines and Healthcare products Regulatory Agency (MHRA) reveal 79 people experienced blood clots after receiving a dose of Vaxzevria (AZD1222), with 19 …

UK will offer under-30s alternative to AZ’s COVID jab Read More »

Paediatric trial of AZ COVID jab ‘halted as a precaution’

Oxford University has suspended a clinical trial of its AstraZeneca-partnered COVID-19 vaccine in children and adolescents while a possible link to rare cases of blood clotting is investigated by the UK drugs regulator.  Around 300 volunteers have been enrolled into the trial, but investigators have decided to pause dosing with the Oxford/AZ vaccine while they …

Paediatric trial of AZ COVID jab ‘halted as a precaution’ Read More »

Could Moderna shot save UK’s under-50s COVID vaccination push?

People in the UK will start receiving doses of Moderna’s COVID-19 vaccine in around two weeks’ time, according to vaccines minister Nadhim Zahawi. The roll-out of the third coronavirus shot will come as the UK exits its second lockdown round, and in time to offset an anticipated dip in supply of the Oxford University/AstraZeneca AZD1222 …

Could Moderna shot save UK’s under-50s COVID vaccination push? Read More »

AZ exits US vaccine plant after mix-up spoils J&J’s COVID jab

AstraZeneca is shifting production of its COVID-19 vaccine away from a plant in Baltimore which also makes Johnson & Johnson’s shot, after human error resulted in the contamination of 15 million doses.  The mix-up at the facility operated by contract manufacturer Emergent BioSolutions resulted in ingredients destined for AZ’s AZD1222 jab being mixed into vials …

AZ exits US vaccine plant after mix-up spoils J&J’s COVID jab Read More »

Boris Johnson slammed for saying “greed” is behind UK vaccine success

Boris Johnson’s sense of humour seems to have got him into trouble again, at the most delicate of times. The Prime Minister reportedly told Conservative backbench MPs on a Zoom call that “capitalism” and “greed” was behind the success of the UK’s COVID-19 vaccination programme, before backtracking after realising he had made a blunder and …

Boris Johnson slammed for saying “greed” is behind UK vaccine success Read More »

States halting AZ jab a ‘disaster’ for EU’s COVID vaccination programme

The decision by around a dozen EU countries to suspend dosing with AstraZeneca’s COVID-19 vaccine is facing criticism, amid fears that it could undermine the response to the pandemic in Europe.  Germany, France, Italy and Spain are among the member states that have announced a suspension of dosing with AZD1222 in the last 24 hours …

States halting AZ jab a ‘disaster’ for EU’s COVID vaccination programme Read More »

J&J’s COVID-19 shot backed for emergency use in EU

The EU’s medicines regulator has recommended granting conditional approval to a fourth COVID-19 vaccine – a single-dose shot from Johnson & Johnson’s Janssen unit – after a review by its human medicines committee.  The CHMP has concluded that the Ad26.COV2.S vaccine can be used in people aged over 18, saying that “the data on the …

J&J’s COVID-19 shot backed for emergency use in EU Read More »

Pfizer/BioNTech COVID jab works against Brazil variant; lab study

A laboratory study suggests Pfizer and BioNTech’s COVID-19 vaccine Comirnaty could be effective against a Brazilian variant of the SARS-CoV-2 virus – known as P.1 – that is worrying health officials around the world.  The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise …

Pfizer/BioNTech COVID jab works against Brazil variant; lab study Read More »

EMA starts rolling review of Sputnik V COVID vaccine

With EU countries breaking ranks in order to get access to the Russian Sputnik V COVID-19 vaccine, the EMA has started a rolling review of the shot.  “EMA will assess Sputnik V’s compliance with the usual EU standards for effectiveness, safety and quality. While EMA cannot predict the overall timelines, it should take less time …

EMA starts rolling review of Sputnik V COVID vaccine Read More »

Germany backtracks on AZ COVID vaccine age restriction

Germany has decided that AstraZeneca’s COVID-19 vaccine should be approved for use in the over-65s after all, reversing its earlier restriction in that age group.  The country’s drugs regulator previously limited use of the vaccine to the under-65s only, claiming that the data in the older age group was inadequate, even though the European Commission …

Germany backtracks on AZ COVID vaccine age restriction Read More »

FDA clears third emergency COVID-19 vaccine from J&J

The FDA has approved emergency use of a third COVID-19 vaccine from Johnson & Johnson’s Janssen Biotech unit, the day after an advisory committee concluded it was safe and effective. Janssen’s Ad26.COV2.S vaccine has been authorised for use in people aged 18 or over after a “comprehensive evaluation of available safety, effectiveness and manufacturing quality …

FDA clears third emergency COVID-19 vaccine from J&J Read More »

FDA reviewer backs J&J COVID jab for emergency OK

Johnson & Johnson’s one-shot coronavirus vaccine is due to be reviewed by an FDA advisory committee on Friday, and according to the regulator meets the requirements for emergency use authorisation. In a briefing document published ahead of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, the FDA says the Ad26.COV2.S vaccine – developed …

FDA reviewer backs J&J COVID jab for emergency OK Read More »

AZ COVID jab efficacy debate is hindering EU’s vaccine drive

The spat between the EU and AstraZeneca over access to the company’s COVID-19 shot led to scathing remarks about its efficacy that now threaten to undermine the EU’s vaccination targets.  The European Commission approved AZ’s AZD1222 vaccine for use in the EU in all adults aged over 18 at the end of January, more than …

AZ COVID jab efficacy debate is hindering EU’s vaccine drive Read More »

Scientists make case for one dose of Pfizer’s COVID jab to stretch supplies

Two researchers have suggested that the second dose of Pfizer and BioNTech’s COVID-19 vaccine could be delayed, as this would increase the number of people that can be protected while supplies are limited without compromising its efficacy.  The two Canadian researchers – Danuta Skowronski and Gaston De Serres – make the suggestion in a letter …

Scientists make case for one dose of Pfizer’s COVID jab to stretch supplies Read More »

UK will start first COVID-19 challenge study “within a month”

Sometime within the next few weeks, young and healthy volunteers will be deliberately exposed to the COVID-19 coronavirus in the UK in what looks set to be the first study of its type worldwide.  The human challenge study has just secured ethics committee approval and will recruit up to 90 volunteers aged 18-30 years, according …

UK will start first COVID-19 challenge study “within a month” Read More »

North Korea ‘launched cyber-attack on Pfizer for COVID-19 jab data’

A news agency is claiming that North Korea launched a cyber-attack on Pfizer in a bid to steal information about its BioNTech-partnered COVID-19 vaccine, citing South Korea’s National Intelligence Service (NIS). The Yonhap agency said the revelation was made during a closed-door meeting of the intelligence committee of South Korea’s National Assembly. According to recent …

North Korea ‘launched cyber-attack on Pfizer for COVID-19 jab data’ Read More »

UK targets COVID-19 variants with new order for CureVac jab

The UK has agreed a 50 million-dose order for a COVID-19 vaccine with German biotech CureVac to support development of a shot that specifically targets emerging variants of the virus. The agreement will see the UK work with CureVac develop “new varieties of vaccines based on messenger RNA technology to be developed quickly against new …

UK targets COVID-19 variants with new order for CureVac jab Read More »

Sputnik V data in Lancet should end “fake news” on its efficacy, says RDIF

The publication of data backing Russia’s COVID-19 vaccine Sputnik V in a peer review journal should bring a campaign to discredit the shot to an end, says the head of the Russian Direct Investment Fund (RDIF). The new data – made available in The Lancet today – give the vaccine a protection rate of 91.6% …

Sputnik V data in Lancet should end “fake news” on its efficacy, says RDIF Read More »

EMA approves AZ’s COVID-19 vaccine – including for over-65s

The EMA has approved AstraZeneca’s COVID-19 vaccine for use in the EU in all adults aged over 18, despite assertions in Germany this week that it shouldn’t be used in elderly people. The conditional marketing authorisation makes AZD1222 the third coronavirus vaccine to be approved for EU use after the Pfizer/BioNTech and Moderna shots, and …

EMA approves AZ’s COVID-19 vaccine – including for over-65s Read More »

Bomb scare sparks evacuation of plant making AZ COVID-19 vaccine

A plant in Wales manufacturing the AstraZeneca COVID-19 vaccine was evacuated on the advice of the authorities today after it was sent a suspicious package. Bomb disposal experts were called in to investigate the parcel at the fill and finish facility in Wrexham, operated by Wockhardt UK, which has the capacity to produce around 300 …

Bomb scare sparks evacuation of plant making AZ COVID-19 vaccine Read More »

UK is first European country to see COVID-19 deaths pass 100,000

More than 100,000 people have died within 28 days of a positive COVID-19 test in the UK, the first European country to meet that grim milestone. The UK is only the fifth country after the US, Brazil, India and Mexico to pass that threshold, after a surge in cases following the holiday period around the …

UK is first European country to see COVID-19 deaths pass 100,000 Read More »

EU eyes tighter COVID-19 vaccine exports as access gets ugly

The EU has hit back at AstraZeneca’s plan to provide fewer doses of its COVID-19 vaccine than expected, saying it wants to see exactly where supplies have been delivered so far.   Moreover, it plans to rush through legislation requiring that all companies producing vaccines against COVID-19 in the EU have to notify the Commission …

EU eyes tighter COVID-19 vaccine exports as access gets ugly Read More »

Pfizer/BioNTech say COVID-19 vaccine works against UK variant

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. The results of the study – published online prior to peer review – are among the first data to indicate that any of the approved coronavirus vaccines can effectively …

Pfizer/BioNTech say COVID-19 vaccine works against UK variant Read More »

Allergic reactions prompt Moderna COVID vaccine pause in California

Public health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine after reports of allergic reactions at one immunisation clinic. According to state epidemiologist Dr Erica Pan, there were a higher-than-expected number of suspected allergic reactions at a community clinic being used to administer the shot, with some …

Allergic reactions prompt Moderna COVID vaccine pause in California Read More »

Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. Approvals for injectable vaccines for COVID-19 are starting to build, but non-injectables like oral and intranasal vaccines could be required if the pandemic is to be fought across all areas of the globe, according …

Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech Read More »

EMA says AstraZeneca’s COVID-19 shot could be approved on 29 January

The European medicines Agency (EMA) said this morning it has received a marketing application from AstraZeneca for its COVID-19 vaccine, already rolling out in the UK, and could give it the go-ahead later this month. The filing for conditional marketing approval is scheduled for review by the EMA’s CHMP human medicine committee at a meeting …

EMA says AstraZeneca’s COVID-19 shot could be approved on 29 January Read More »

Moderna’s COVID-19 vaccine is third approved in UK

The UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although supplies are not expected to arrive for several weeks. Moderna’s mRNA-1273 is the third COVID-19 vaccine to be approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the second mRNA vaccine after …

Moderna’s COVID-19 vaccine is third approved in UK Read More »

Bayer joins the COVID-19 vaccine push, backing CureVac shot

Shortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to roll the shot out at scale if it works as hoped. Bayer has joined forces with the German biotech to support the development and supply of CVnCoV, an mRNA candidate using a similar technology to the Pfizer/BioNTech …

Bayer joins the COVID-19 vaccine push, backing CureVac shot Read More »

AZ COVID-19 vaccine cleared in UK, dosing to start next week

The UK has approved AstraZeneca and Oxford University’s COVID-19 vaccine AZD1222 in another significant step forward in the fight against the pandemic, with first doses due to be administered on Monday. The UK government has already ordered 100 million doses of the adenovirus-based shot, enough to vaccinate 50 million people, adding to the 40 million …

AZ COVID-19 vaccine cleared in UK, dosing to start next week Read More »

Vulnerable should all get COVID-19 shot before summer, says NHS chief

NHS England’s chief executive Sir Simon Stevens has said that all vulnerable people over the age of 50 will be offered a COVID-19 vaccine by “late spring” in a message to healthcare workers. The prediction comes after the NHS announced on Christmas Eve that more than half a million people had received the Pfizer/BioNTech shot …

Vulnerable should all get COVID-19 shot before summer, says NHS chief Read More »

Moderna’s COVID-19 vaccine is second for US after FDA green light

As expected, the FDA has moved swiftly ahead with emergency approval of Moderna’s COVID-19 vaccine after a positive assessment at its vaccines advisory committee. The authorisation means that around six million more vaccine doses can now be rolled out in the US coronavirus immunisation programme, adding to the almost three million doses of Pfizer/BioNTech’s already-approved …

Moderna’s COVID-19 vaccine is second for US after FDA green light Read More »

Scientists and medics turn to TikTok to reassure public on vaccine safety

Tik Tok is unlikely to spring to mind as a source of reliable information about complex issues, but scientists are using it to fly the flag for COVID-19 vaccines and other health topics. The social media platform, which allows users to share short and often frivolous video clips, has a growing number of experts using …

Scientists and medics turn to TikTok to reassure public on vaccine safety Read More »

FDA backs Moderna COVID-19 shot ahead of emergency use vote

Moderna looks odds on to claim emergency use authorisation from the FDA for its COVID-19 vaccine this week, after the regulator published a report endorsing its safety and rating its efficacy at 94.5%. The document has been published just after the US started the rollout of Pfizer and BioNTech’s vaccine after it got an emergency …

FDA backs Moderna COVID-19 shot ahead of emergency use vote Read More »

Pfizer/BioNTech COVID-19 vaccinations start across the US

Hospitals in the US have started vaccinating their front-line staff against COVID-19, as deaths in the country crossed the 300,000 threshold with more than 200,000 new cases reported yesterday. Shipments of Pfizer/BioNTech’s mRNA vaccine BNT-162b are being shipped to hundreds of hospitals and other distribution facilities across the US, with the first three million doses …

Pfizer/BioNTech COVID-19 vaccinations start across the US Read More »

Cyberattack targets EMA, hacks COVID-19 vaccine data

The European Medicines Agency (EMA) says it suffered a cyberattack, with documents relating to a Pfizer and BioNTech’s COVID-19 vaccine accessed. In a terse statement, the EU regulator confirmed its security had been breached and said it had launched an investigation with law enforcement, but would not be providing any additional information while that probe …

Cyberattack targets EMA, hacks COVID-19 vaccine data Read More »

Social media erupts as anti-vaxxers respond to COVID-19 vaccine approval

In the midst of the jubilation about the UK’s emergency approval of Pfizer/BioNTech’s COVID-19 shot in the UK came the depressingly inevitable round of anti-vaccine social media activity and lobbying. The green light for BNT162b was swiftly followed by posts on Twitter likening the vaccine to thalidomide – the drug that notoriously resulted in thousands …

Social media erupts as anti-vaxxers respond to COVID-19 vaccine approval Read More »

Moderna seeks COVID vaccine okay as data backs 94% efficacy

Moderna has said it will file for US, European and UK emergency approval of its coronavirus vaccine straight away, after reporting updated phase 3 results for the shot. The primary analysis from the 30,000-subject COVE trial of mRNA-1273 – based on 196 confirmed cases of COVID-19 – has come in at 94% efficacy, with 185 …

Moderna seeks COVID vaccine okay as data backs 94% efficacy Read More »

Russian Sputnik COVID-19 vaccine ‘will cost less than $10 a dose’

The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 per dose – or $20 per two-dose course – on the same day as revealing new clinical data with the shot. Sputnik V’s efficacy has remained high at 91.4% according to the latest analysis, which comes from …

Russian Sputnik COVID-19 vaccine ‘will cost less than $10 a dose’ Read More »

UK eyes access deal as Moderna’s COVID-19 shot hits the mark

Moderna is the third group in a week to report encouraging phase 3 data with a coronavirus vaccine, saying today that its mRNA-1273 shot had an efficacy of 94.5% in the 30,000-patient COVE study. The results set up an emergency use authorisation (EUA) filing in the US “within weeks” according to the company, and the …

UK eyes access deal as Moderna’s COVID-19 shot hits the mark Read More »

Russia claims 92% efficacy for Sputnik COVID-19 shot

In the second positive piece of COVID-19 vaccine news in a week, Russia’s Sputnik V candidate has been shown to be 92% effective at the interim point of a 40,000-patient study. The preliminary assessment is based on 20 coronavirus cases split between the vaccinated and placebo arms of the study at 21 days, according to …

Russia claims 92% efficacy for Sputnik COVID-19 shot Read More »

MHRA looks to AI to hunt for COVID-19 vaccine side effects

The UK drugs regulator has awarded a £1.5 million tender to a software company for an artificial intelligence tool that will be used to process “the expected high volume of COVID-19 vaccine adverse drug reactions (ADRs).” The tender awarded to Maidenhead, Berkshire-based GenPact UK aims to “ensure that no details from the ADRs…are missed” as …

MHRA looks to AI to hunt for COVID-19 vaccine side effects Read More »

Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Japan supply deal

Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 billion in deposits for the shot. The figure was revealed by CEO Stéphane Bancel in Moderna’s third-quarter results call on which he also highlighted a new agreement to supply …

Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Japan supply deal Read More »

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end of earnings guidance for the year. The bounce-back wasn’t enough to ease investor worries however – with fresh lockdowns …

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares Read More »

Russia’s COVID-19 vaccine filed with WHO, as MHRA reviews Moderna shot

Russia’s sovereign wealth fund has filed applications with the World Health Organization (WHO) that if approved could see the Sputnik V coronavirus vaccine backed for use in many countries around the world. The applications are for two WHO mechanisms, aimed at providing a route to market for vaccines, drugs and other healthcare products that answer …

Russia’s COVID-19 vaccine filed with WHO, as MHRA reviews Moderna shot Read More »

Moderna nears COVID-19 vaccine finish line as it wraps up study enrolment

Moderna is close to completing its phase 3 trial of COVID-19 vaccine candidate mRNA-1273 after completing recruitment of the 30,000 subjects in the trial. It’s also revealed that more than 25,000 of them have already received the second dose of the shot in the COVE study, putting it in contention to be the first coronavirus …

Moderna nears COVID-19 vaccine finish line as it wraps up study enrolment Read More »

AZ, J&J COVID-19 vaccine trials okay to restart in US

US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot. Separately, Johnson & Johnson has also announced it is resuming recruitment in a phase 3 trial of  its coronavirus candidate JNJ-78436735, …

AZ, J&J COVID-19 vaccine trials okay to restart in US Read More »

Pfizer ‘ready to roll’ if BioNTech COVID-19 shot is approved

Pfizer now has hundreds of thousands of doses of BioNTech’s COVID-19 vaccine coming off the production line at a facility in Belgium, ready for delivery if it clears phase 3 testing. The output of the plant in Puurs should allow the partners to have 100 million doses of BNT162b2 ready for delivery by the end …

Pfizer ‘ready to roll’ if BioNTech COVID-19 shot is approved Read More »

Sanofi preps trials of second COVID-19 shot, as Russia approves another

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. The French drugmaker’s Sanofi Pasteur vaccines division says it is planning a phase 1/2 trial of the mRNA-based vaccine, called MRT5500, before the end of the year. …

Sanofi preps trials of second COVID-19 shot, as Russia approves another Read More »

EU ramps up supply of COVID-19 vaccine, drugs

The European Commission has taken its advance orders for potential COVID-19 vaccines to more than 1.1 billion, after signing a supply deal for up to 400 million doses of Johnson & Johnson’s experimental candidate. The agreement is the third for coronavirus vaccine supply for the EU, coming after earlier deals with AstraZeneca and Sanofi/GlaxoSmithKline, and …

EU ramps up supply of COVID-19 vaccine, drugs Read More »

FDA gives COVID-19 vaccine ‘advice’ after White House blocks guidance

The FDA may have been blocked from issuing stricter guidelines for emergency approval of COVID-19 vaccines by the Trump administration, but it has still managed to make its new approach public. The regulator published “advice” to vaccine developers as part of documentation prepared for a vaccine advisory panel scheduled to convene later this month. The …

FDA gives COVID-19 vaccine ‘advice’ after White House blocks guidance Read More »

Moderna’s COVID vaccine works in older people, according to new data

Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19. An analysis of the latest data from a phase 1 trial showed that in 20 older adults given the vaccine – ten between …

Moderna’s COVID vaccine works in older people, according to new data Read More »

Chinese starts vaccinating key workers against COVID-19; report

China has already granted emergency use authorisation to multiple COVID-19 vaccines developed by domestic drugmakers and started dosing key workers, according to local media reports. Zheng Zhongwei, head of China’s COVID-19 vaccine development task force, made the revelation on Chinese television, saying that the vaccines were being used in people at high-risk of contracting SARS-CoV-2, …

Chinese starts vaccinating key workers against COVID-19; report Read More »

EU places firm order for AZ/Oxford Uni’s ChAdOx1 COVID-19 vaccine

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. ChAdOx1 – which is in large-scale phase 2/3 trials – was licensed by AZ in April and renamed AZD1222, and …

EU places firm order for AZ/Oxford Uni’s ChAdOx1 COVID-19 vaccine Read More »

Anger at US deal for Moderna’s ‘taxpayer-funded’ COVID-19 vaccine

The US government has signed another big coronavirus vaccine supply deal, snapping up 100 million doses of Moderna’s mRNA jab for a little over $1.5 billion –around $15 per dose or $30 per course. That’s a steep discount on the $32 to $37 price per dose in its earlier smaller deals, revealing that purchasing power …

Anger at US deal for Moderna’s ‘taxpayer-funded’ COVID-19 vaccine Read More »

Certara adds to its COVID-19 toolkit with virtual trials module

Drugmakers have been working with data specialist Certara on a new tool that they hope could speed up the development of  vaccines for COVID-19. The new “biosimulation” tool is designed to make it easier for vaccine candidates across multiple patient populations through the use of virtual patients and trials, providing insights before any real-life studies …

Certara adds to its COVID-19 toolkit with virtual trials module Read More »

UK places order for 60m doses of Sanofi/GSK’s COVID-19 vaccine

The UK government has signed its fourth coronavirus vaccine deal, snapping up 60 million doses of an experimental shot being developed by Sanofi and GlaxoSmithKline. The order has come in even before the vaccine has started clinical development, with a phase 1/2 trial not due to get underway until September. Sanofi is providing the vaccine …

UK places order for 60m doses of Sanofi/GSK’s COVID-19 vaccine Read More »

US places $1.95 billion order for Pfizer/BioNTech’s COVID-19 vaccine

The US government has agreed to pay Pfizer and BioNTech $1.95 billion to secure access to 100 million doses of their coronavirus vaccine on approval, just days after promising results in a clinical trial. The deal – part of the Trump administration’s Operation Warp Speed that aims to deliver 300 million coronavirus vaccines in early …

US places $1.95 billion order for Pfizer/BioNTech’s COVID-19 vaccine Read More »

Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analyst

JP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high even if its COVID-19 vaccine mRNA-1273 succeeds in clinical trials. Moderna’s share price has rocketed 385% this year, driven by the development of mRNA-1273, but the analysts think there are too many unknowns surrounding the coronavirus pandemic …

Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analyst Read More »

‘Promising’ data on Oxford/AZ, CanSino coronavirus vaccines

Data from more than 1,000 healthy volunteers dosed with a coronavirus vaccine developed at Oxford University and AstraZeneca suggest the shot is safe and stimulates an immune response against the virus. The first phase 1/2 results with the ChAdOx1 vaccine – also known as AZD122 – were published today in medical journal The Lancet and …

‘Promising’ data on Oxford/AZ, CanSino coronavirus vaccines Read More »

GSK-partnered Medicago starts trials of plant-based COVID-19 vaccine

Medicago has started dosing healthy volunteers in the first human trial of its candidate vaccine for COVID-19, a few days after partnering with GlaxoSmithKline on the project. The Quebec, Canada-based biotech is using a different approach with its vaccine than the other candidates in clinical testing – 22 at last count according to the World …

GSK-partnered Medicago starts trials of plant-based COVID-19 vaccine Read More »

The Most Promising COVID-19 Vaccine Candidates In The Pipeline To Watch Out For

Coronavirus pandemic has infected over 10 million people worldwide with over half a million casualties. The lock-down and other restriction measures such as social distancing have somehow slowed down the virus spread initially. But these steps have caused many serious humanitarian and economic consequences. Countries worldwide are now easing the restrictions to bring their economies …

The Most Promising COVID-19 Vaccine Candidates In The Pipeline To Watch Out For Read More »

Types of COVID-19 Vaccines Being Developed Globally

A vaccine to prevent coronavirus disease 2019 (COVID-19) is being vouched as the only and the best hope to end the pandemic that has claimed the lives of more than 330,000 people worldwide. Pharmaceutical companies and researchers across the world are in a race to develop a safe and effective vaccination for COVID-19. Many such …

Types of COVID-19 Vaccines Being Developed Globally Read More »

No Approved Drug or Chemical For Prevention and Treatment of Coronavirus

The health authorities have time and again requested people not to take any drug or medicines by themselves in an attempt to cure coronavirus. When something is available for the treatment of COVID-19, it will be publicly announced by the World Health Organization (WHO). The WHO is already coordinating with the pharmaceutical companies and researchers …

No Approved Drug or Chemical For Prevention and Treatment of Coronavirus Read More »